Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Humacyte, Inc. (HUMA : NSDQ)

• Company Description    Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C. Number of Employees: 146

• Price / Volume Information    Yesterday's Closing Price: $4.71 Daily Weekly Monthly 20 Day Moving Average: 417,814 shares Shares Outstanding: 103.00 (millions) Market Capitalization: $485.15 (millions) Beta: 0.23 52 Week High: $17.45 52 Week Low: $4.27 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -33.66% -27.36% 12 Week -17.94% -7.78% Year To Date -35.03% -20.63%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2525 EAST NORTH CAROLINA HIGHWAY 54 - DURHAM,NC 27713 USA ph: 919-313-9633 fax: - investors@humacyte.com http://www.constellationalpha.com

• General Corporate Information    Officers Laura E. Niklason - President; Chief Executive Officer and Director Dale A. Sander - Chief Financial Officer; Chief Corporate Developme Gordon M. Binder - Director Michael T. Constantino - Director Brady W. Dougan - Director Peer Information Humacyte, Inc. (CORR.) Humacyte, Inc. (RSPI) Humacyte, Inc. (CGXP) Humacyte, Inc. (BGEN) Humacyte, Inc. (GTBP) Humacyte, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 44486Q103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/12/22 Share - Related Items Shares Outstanding: 103.00 Most Recent Split Date: (:1) Beta: 0.23 Market Capitalization: $485.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.87 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.67 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 50.32% vs. Previous Quarter: 31.64% ROE 03/31/22 - -88.04 12/31/21 - -124.53 09/30/21 - - ROA 03/31/22 - -28.30 12/31/21 - -32.75 09/30/21 - - Current Ratio 03/31/22 - 19.45 12/31/21 - 20.75 09/30/21 - 11.49 Quick Ratio 03/31/22 - 19.45 12/31/21 - 20.75 09/30/21 - 11.49 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -3,996.16 12/31/21 - -2,096.91 09/30/21 - - Book Value 03/31/22 - 1.01 12/31/21 - 1.19 09/30/21 - 0.74 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.47 12/31/21 - 0.40 09/30/21 - 0.47 Debt-to-Capital 03/31/22 - 31.75 12/31/21 - 28.40 09/30/21 - 31.98

Powered by Zacks Investment Research ©